Compare abrdn Income Credit Strategies Fund (ACP) vs Danaher Corporation (DHR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Danaher Corporation — how do they compare? abrdn Income Credit Strategies Fund trades at $5.23 (market cap $656.21M), while Danaher Corporation trades at $190.62 (market cap $137.44B). The key difference: Danaher Corporation is far larger — about 209.4× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays the higher dividend (17.78%). Which is the better fit depends on your goals.
| ACP | DHR | |
|---|---|---|
Market Cap | $656.21M | $137.44B |
Sector | Financials | Health |
52-Week High | $5.98 | $242.05 |
52-Week Low | $5.01 | $161.91 |
Dividend Yield | 17.78% | 0.82% |
Enterprise Value | — | $150.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
Danaher (DHR) trades at $190.77, down 1.47% on the day, with a bullish technical outlook supported by moving averages and strong institutional support. The company maintains solid fundamentals with consistent earnings beats, a 14.89% net income margin, and positive cash flow of $2.54B in 2025. Recent developments include the Masimo acquisition approval and new product launches in the biotechnology segment.
The stock presents a compelling opportunity with 69% analyst buy ratings and a $214.73 price target suggesting 12.6% upside. Key risks include revenue stagnation from $24.6B in 2025 to projected $24.8B in 2026 and the recent $172.5M legal settlement over pandemic-era disclosures. Biotechnology segment growth at 7% remains a positive catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
